The global fertility market is estimated to grow to ~$50B by 2030 with nearly 1/8 couples having trouble conceiving. Advances in technology are making reproductive health options more accessible from both a convenience and affordability standpoint. Bea Fertility is a healthcare startup offering at-home fertility treatments via a kit offered through subscription. Traditional fertility options like IVF need to be done at a fertility center and come at exorbitant cost. Bea uses ICI, a technique that’s similarly effective to other treatment options, but only costs £300/month. The company is focused on supporting the entire conception journey and offers ovulation tracking, guidance, and an expert network. Presently pre-launch, Bea is in the process of gaining regulatory approval and expects to launch by the end of the year. London TechWatch caught up with CEO and Cofounder Tess Cosad to learn more about the importance of making fertility treatments accessible, the company’s upcoming launch, strategic plans, and recent round of funding from Calm/Storm VC and QVentures.
All human progress operating in service of bettered humanity is a response to one essential question: how do we evolve current knowledge into revolutionary concepts? In my four decades as an inventor, I have often found my response to this question to be one of medically-directed invention.
Scientific exploration of the microbiome represents the opening of one of the greatest new areas of science in decades, perhaps centuries. It has the potential to rival Einstein’s impact on physics or the double helix on understanding biology. While young, this area shows historic potential across a dizzying expanse of health and human experience.
Prokarium is developing Vesibax, an innovative, safe, and effective microbial immunotherapy (MI) for early-stage bladder cancer, a disease with afflicts over 550,000 individuals globally every year. CEO Ted Fjallman to learn more about Prokarium’s upcoming pipeline of novel therapies, its current focus, and recent funding round from investors that include Korea Investment Partners (KIP), Flerie Invest, Riyadh Valley Company (RVC), and the UK Government’s Future Fund.
Neuroscience has always been a focus area for Social Starts and Joyance Partners and should continue to be due to the large and clear unmet need. Stress, anxiety, mental illness, and their associated impacts are at all-time highs. People seem desperate for solutions. Science points toward many potential new approaches. We also recognize that there […]
Longevity and Aging Economy will be one of the core investment areas for Social Starts for the remainder of 2020. Longevity ties strongly into Health and Happiness: “Healthspan”—the number of years a person can expect to live with full health and no activity limitations—is an emerging concept in this area and should stand at the […]
Because of the inextricable tie between health and happiness, there exists an equally strong connection between happiness and health. Now, powerful new science is opening whole new categories of products capable of contributing to happiness. Therefore, we see Health Tech as a central investment focus area.
We believe that successful digital brands have these characteristics…
Approximately 70%-80% of care homes are reliant on pen and paper and manual processes to run their operations and record data. Log my Care is the free care management software platform that features an intuitive interface that enables care providers to deliver exceptional care and record plans with a few clicks. Founder Sam Hussain shares some more insight on the inspiration for the company, how the pandemic led to the rapid development of new features, and the company’s latest funding round.
Pitch decks come in a lot of flavors. We’ve seen five pages, we’ve seen fifty. We’ve seen them sparsely punctured with bullet points, we’ve seen what might have happened if David Foster Wallace wrote a novel in PowerPoint. Where’s the golden mean? What can you throw away and what sparks joy?